AAA
FHTX icon

Affinity Asset Advisors’s Foghorn Therapeutics FHTX Stock Holding History

Affinity Asset Advisors’s Portfolio FHTX Stock Details FHTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-136,771
Closed -$848K – 79
2023
Q1 		$848K Buy
136,771
+26,780
+24% +$175K 0.28% 60
2022
Q4 		$702K Buy
+109,991
New +$829K 0.28% 54

Other funds holding FHTX

FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
EC
Euclidean Capital New York $392M AUM 31.85% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RJA
Raymond James & Associates St Petersburg, Florida $164B AUM 33.91% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Affinity Asset Advisors's FHTX Position: Q2 2023 in Review

Affinity Asset Advisors sold out of Foghorn Therapeutics (FHTX) in Q2 2023, closing a stake of 136,771 shares — an estimated $848K sold.

Affinity Asset Advisors first reported a position in FHTX in Q4 2022 and held it in 2 quarters. The position peaked at $848K in Q1 2023. 59 funds tracked by Wall St. Rank hold FHTX as of Q2 2023.

  • Affinity Asset Advisors reported no remaining Foghorn Therapeutics position as of Q2 2023 after selling out during the quarter.
  • Affinity Asset Advisors sold 136,771 Foghorn Therapeutics shares in Q2 2023, an estimated $848K.
  • Affinity Asset Advisors first reported a position in Foghorn Therapeutics in Q4 2022 and held it in 2 quarters.
  • Affinity Asset Advisors's Foghorn Therapeutics position peaked at $848K in Q1 2023.
  • 59 funds tracked by Wall St. Rank held Foghorn Therapeutics as of Q2 2023.

Based on Affinity Asset Advisors's 13F filing for Q2 2023, filed 14 Aug 2023.